Regen BioPharma Inc (RGBP)

[Carter]

III: Nr2f6 thereapies "resulting in striking anti-tumor effects in different advanced mouse models relevant to human cancer."

According to all our preclinical data, high NR2F6 expression is likely to critically contribute to the immune-suppressed state of tumor antigen-specific TILs, thus limiting the host’s anti-tumor immune response. Absence of NR2F6, either through genetic ablation in Nr2f6 knockout mice or by the means of siRNA knockdowns, increases the immune system’s ability to mount effective immune responses, resulting in striking anti-tumor effects in different advanced mouse models relevant to human cancer.
https://www.nature.com/articles/s41467-018-04004-2